Advertisement

Topics

"Adaptimmune Announces Preliminary Results from Early Phase Trial" Drugs and Medication Database

09:15 EST 17th February 2019 | BioPortfolio

Here are the most relevant "Adaptimmune Announces Preliminary Results from Early Phase Trial" Drugs and Medications that we have found in our database.

More Information about "Adaptimmune Announces Preliminary Results from Early Phase Trial" on BioPortfolio

We have published hundreds of Adaptimmune Announces Preliminary Results from Early Phase Trial news stories on BioPortfolio along with dozens of Adaptimmune Announces Preliminary Results from Early Phase Trial Clinical Trials and PubMed Articles about Adaptimmune Announces Preliminary Results from Early Phase Trial for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Adaptimmune Announces Preliminary Results from Early Phase Trial Companies in our database. You can also find out about relevant Adaptimmune Announces Preliminary Results from Early Phase Trial Drugs and Medications on this site too.

Showing "Adaptimmune Announces Preliminary Results from Early Phase Trial" Drugs and Medications, all 2

Possibly Relevant

Hexalen [eisai inc.]

Hexalen

Iclusig [millennium pharmaceuticals, inc.]

These highlights do not include all the information needed to use ICLUSIG safely and effectively. See full prescribing information for ICLUSIG. ICLUSIG(ponatinib) tablets, for oral use Initial U.S. Approval: 2012



Advertisement
Quick Search
Advertisement
Advertisement